We reasoned that the activation of SGK3 may be a compensatory mechanism to substitute the blockade of the Akt signalling pathway, which causes HCC cells to tolerate the treatment of PI3K inhibitors. The gene discussed is SGK3; the disease is hepatocellular carcinoma.